Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019
August 06, 2019 16:05 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday, August...
Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan
July 31, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
In Network Access for More Than 6 Million Members PARSIPPANY, NJ, July 31, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has contracted with Blue...
Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®
July 29, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Four Million Members Gain in-Network Access PARSIPPANY, NJ, July 29, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has entered in to a contract...
Interpace Announces New Agreement with SelectHealth
July 22, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement...
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
July 18, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics...
Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners
July 15, 2019 16:10 ET
|
Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET PARSIPPANY NJ, July 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the...
Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
June 20, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by...
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
June 13, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Rome, ITALY, June 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that...
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 16:05 ET
|
Interpace Diagnostics Group, Inc.
Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast Monday May 13, 2019 at 4:30...
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
May 09, 2019 06:55 ET
|
Interpace Diagnostics Group, Inc.
Company to Host Fellowship and Key Opinion Leader Programs PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that data from an...